Glykrez Total 30 Tablet SR is a combination oral antidiabetic medication formulated for the management of type 2 diabetes mellitus. Each sustained-release tablet contains Gliclazide 30 mg, Pioglitazone 15 mg, and Metformin 500 mg, which work synergistically to improve glycemic control. Gliclazide, a sulfonylurea derivative, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Pioglitazone, a thiazolidinedione, improves insulin sensitivity in peripheral tissues, particularly muscle and adipose tissue, facilitating increased glucose uptake and utilization. Metformin, a biguanide, primarily acts by decreasing hepatic gluconeogenesis and improving peripheral glucose uptake, contributing to reduced fasting and postprandial blood glucose levels. The sustained-release formulation ensures a gradual release of active ingredients, promoting better tolerability and adherence by minimizing gastrointestinal side effects commonly associated with metformin. Glykrez Total 30 is indicated for patients inadequately controlled on monotherapy or dual therapy, providing a comprehensive approach to glycemic management. It should be used under medical supervision with regular monitoring of blood glucose, renal function, and liver enzymes. Contraindications include type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Patient education on lifestyle modification and adherence is essential for optimal therapeutic outcomes.